Compare KB Financial Group, Inc. (KB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? KB Financial Group, Inc. trades at $117.53 (market cap $41.21B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: KB Financial Group, Inc. pays a 2.67% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| KB | XBI | |
|---|---|---|
Market Cap | $41.21B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $124.01 | $164.28 |
52-Week Low | $77.50 | $86.92 |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial trades at $117.85, down 2.39% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.36, P/B of 0.98, and net income margin of 27.82%. Recent earnings beats in Q1 and Q2 2026 highlight operational strength, while cash flow trends show variability with a net inflow of $4.41T in 2025.
The outlook is positive given earnings momentum and undervaluation relative to peers, but risks include volatile cash flows and dependence on interest rates. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism for upside potential amid economic uncertainties.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
